Products
CBL antibody
- Product Name
- CBL antibody
- Catalogue No.
- FNab01317
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- Cas-Br-M (murine) ecotropic retroviral transforming sequence
- Alternative Names
- CBL2 antibody, RNF55 antibody
- UniProt ID
- P22681
- Observed MW
- 117 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:500 - 1:2000; IHC: 1:50 - 1:100
Validated Images
MCF7 cells were subjected to SDS PAGE followed by western blot with FNab01317(CBL antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded human prostate using FNab01317(CBL antibody) at dilution of 1:100
- Background
- This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder.
